BioSpace News Archive

Zai Lab Limited announced that the 2023 National Reimbursement Drug List released by China’s National Healthcare Security Administration has been updated to include the following medicines and indications.

HUTCHMED Limited announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration, on January 1, 2024 the updated National Reimbursement Drug List will continue to include ELUNATE® and SULANDA® at the same terms as the current two-year agreement.

Innovent Biologics, Inc. announces that, the National Reimbursement Drug List has been updated to renew and include the seventh indication of PD-1 inhibitor TYVYT® in negotiation list, and include the eighth indication of BYVASDA® in general list.

Bryn Pharma, LLC, a privately held pharmaceutical company dedicated to finding a novel and convenient way for patients and caregivers to treat anaphylaxis, today announced data from the Company’s pivotal clinical study for its investigational epinephrine nasal spray (ENS), NDS1C, have been published online by the Journal of Allergy and Clinical Immunology (JACI): Global.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company’s board of directors, effective immediately.

Stem cell transplantation is a potentially curative treatment for sickle cell disease (SCD), but it is not feasible for most people, often due to a lack of suitable donors or the inability to tolerate the intensive chemotherapy required as part of the treatment.

Patients with newly diagnosed multiple myeloma (MM) who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and dexamethasone (VRd) showed significantly higher rates of survival without disease progression compared with those who received standard care alone in a phase III trial being reported during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

Ligand Pharmaceuticals Incorporated hosted an Investor and Analyst Day in New York City earlier. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance.

SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and data science to redefine precision medicine for cancer with software tools, recently presented new data from its TumorSight and PhenoScope platforms at the 46th Annual San Antonio Breast Cancer Symposium (SABCS), held from December 5-9, 2023.

According to the latest research by nova one advisor, the global Biosimilars market size was exhibited at USD 22.19 billion in 2022 and it is expected to hold around USD 97.05 billion by 2032, growing at a CAGR of 15.9% from 2023 to 2032.